APP and breast cancer: PN2 has a homozygous missense mutation (p.R1028C) predicted to be ‘likely benign’ and has no congenital abnormalities – although chronic lymphocytic leukaemia and breast cancer were reported, suggesting a possible HBOC (BRCA1) phenotype (37).